Elucid vs Tempus AI Imaging

Elucid works as a service. A physician sends CCTA images, trained analysts segment a 3D model, and the software quantifies coronary plaque, which makes a coronary CTA program its buyer. Its non-invasive FFR-CT analysis is pending FDA review. Tempus says Pixel integrates with existing PACS, EHR, worklist, notification and dictation systems, and lists automated lesion segmentation, longitudinal tracking and RECIST-style response reports for oncology on CT and MR. An oncology service tracking lesions across CT and MR is Tempus's buyer, as is a cardiac MR lab, since an updated Pixel with a special 510(k) in September 2025 generates T1 and T2 maps inline from raw data. A US lung service gets nodule detection only through a third-party engine, because Pixel Lung is cleared but not indicated for lung nodule detection.